Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

Nathan P. Wiederhold

Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; wiederholdn@uthscsa.edu

Abstract: Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established classes or with mechanisms of action similar to clinically available antifungals (ibrexafungerp, rezafungin, oteseconazole, opelconazole, MAT2203) that have been modified in order to improve certain characteristics, including enhanced pharmacokinetics and greater specificity for fungal targets. Many of the antifungals under development also have activity against Candida and Aspergillus strains that have reduced susceptibility or acquired resistance to azoles and echinocandins, whereas others demonstrate activity against species that are intrinsically resistant to most clinically available antifungals. The tolerability and drug–drug interaction profiles of these new agents also appear to be promising, although the number of human subjects that have been exposed to many of these agents remains relatively small. Overall, these agents have the potential for expanding our antifungal armamentarium and improving clinical outcomes in patients with invasive mycoses.

Keywords: pharmacodynamics; antifungals; mechanism of action; resistance; olorofim; manogepix; ATI-2307; GR-2397; ibrexafungerp; rezafungin; oteseconazole; opelconazole; encochleate amphotericin B; MAT2203

1. Introduction

For decades, clinically available antifungals used to treat invasive mycoses have primarily targeted ergosterol, either by binding to it (i.e., polyenes) or through the inhibition of its biosynthesis (i.e., azoles). During the last 20 years, new members of the azoles, including the extended spectrum triazoles, voriconazole, posaconazole, and isavuconazole; lipid formulations of amphotericin B; and the echinocandins, which lack major toxicities and drug–drug interactions due to their fungal-specific mechanism of action, have become available and have led to improvements in clinical outcomes against certain mycoses [1,2]. However, these antifungals are not without limitations, including adverse effects/toxicities associated with amphotericin B and the azoles, and significant drug–drug interactions with the azoles due to interactions with mammalian cytochrome P450 (CYP450) enzymes [1]. The spectrum of activity of the echinocandins is narrow compared to amphotericin B and the azoles, and these antifungals must be administered intravenously, limiting their long-term use. The development of resistance is also of growing concern for the azoles and the echinocandins [3].

Currently, new antifungals with novel mechanisms of action are being developed, including those in Phase II and III clinical trials. These include manogepix, olorofim, ATI-2307, and GR-2397 [4,5]. In addition, other agents with mechanisms of action identical or similar to clinically available antifungals, but with distinct advantages, are also in development, including ibrexafungerp, rezafungin, oteseconazole, opelconazole, and the encochleate amphotericin B formulation, MAT2203. This review discusses the pharmacodynamics (i.e., mechanisms of action), mechanisms of resistance, spectrum of activity, and the pharmacokinetic/pharmacodynamic (PK/PD) parameters of these agents. In addition, their tolerability...
and drug–drug interaction profiles, as they relate to the mechanisms of action, are also reviewed. Those that are in late-stage clinical development or have recently been approved by the U.S. Food and Drug Administration for limited indications are shown in Table 1, and their structures/mechanisms of action and spectrums of activity are shown in Figure 1 and Table 2, respectively. The Clinical and Laboratory Standards Institute (CLSI) has also established and published acceptable minimum inhibitory concentration/minimum effective concentration (MIC/MEC) ranges and modal values for several of these agents (i.e., ibrexafungerp, manogepix, olorofim, and rezafungin) against quality control and reference strains that are available from the American Type Culture Collection (ATCC) [6,7].

Table 1. Antifungals in late-stage clinical development, routes of administration, pharmacokinetic/pharmacodynamic (PK/PD) parameters associated with efficacy, tolerability/adverse effects and drug interactions, and current clinical trials. Cmax = peak bloodstream concentration; Cmin = trough bloodstream concentration; AUC = area under concentration curve; fAUC = free drug area under concentration curve; MIC = minimum inhibitory concentration; MEC = minimum effective concentration; CYP450 = cytochrome P450 enzyme; CYP3A4 = cytochrome P450 3A4 enzyme. Information regarding current clinical trial status was obtained from [https://clinicaltrials.gov/](https://clinicaltrials.gov/) (accessed on 8 July 2022).

| Agent and Company Developing | Routes of Administration | PK/PD Parameter Associated with In Vivo Efficacy | Tolerability/Adverse Effects and Drug Interactions | Current Clinical Trials (Number and Phase) |
|-----------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|
| Manogepix (APX001A) Pfizer  | Intravenous and oral     | AUC/MIC vs. yeasts (fAUC/MIC 1.35–22.54)       | Well-tolerated in Phase I and II clinical studies Drug interaction profile not yet known | Candidemia/invasive candidiasis (NCT05421858, Phase III) |
| Olorofim (F901318) F2G      | Intravenous and oral     | Cmin/MIC (Cmin/MIC 3–16.5 vs. A. fumigatus)   | Well-tolerated in Phase I studies with no serious adverse effects | Invasive aspergillois (NCT05101187, Phase III) |
| Ibrexafungerp (SCY-078) Scynexis | Oral (Intravenous formulation under development) | AUC/MIC vs. Candida (fAUC/MIC 0.1–1.7) | Potential for drug interactions, as it is metabolized by CYP3A enzymes and is a weak inhibitor of CYP3A4 | Complicated vulvar vaginal candidiasis (NCT0599641, Phase III) |
| Rezafungin (CD101) Cidara   | Intravenous              | AUC/MIC vs. Candida (fAUC/MIC 0.07–11.65)     | Potential for drug interactions, as it is metabolized by CYP3A4 and is also an inhibitor of CYP2C8 and 3A4 | Invasive pulmonary aspergillois (NCT03672292, Phase III) |
| Oteseconazole (VT-1161) Mycovia | Oral Undefined, but most likely AUC/MIC (similar to triazoles) | AUC/MIC vs. Candida (fAUC/MIC 0.07–11.65) | Well-tolerated in Phase I and II clinical studies; some infusion-related reactions with higher doses | Antifungal prophylaxis in adults undergoing allogeneic stem cell transplantation (NCT04368559, Phase III) |

Note: The table uses abbreviations for PK/PD parameters and clinical trials. For a comprehensive understanding, consult the original sources.
**Novel Mechanisms of Action**

| Class & Mechanism of Action (gene of interest) |
|-----------------------------------------------|
| **Manogepix (APX001A)**                       |
| N-phosphono-oxymethyl - Inhibition of acyltransferase Gwt1, part of GPI-anchored protein maturation pathway (GWT1) |

| **Olorofim (F901318)**                         |
| Orotomide - Reversible inhibition of dihydroorotate dehydrogenase, part of pyrimidine biosynthesis (DHODH) |

**Mechanisms of Action Similar to or Same as Available Antifungals**

| Class & Mechanism of Action (gene of interest) |
|-----------------------------------------------|
| **Ibrexafungerp (SCY-078)**                   |
| Triterpenoid - Non-competitive inhibition of 1,3-β-D-glucan synthase, depleting 1,3-β-D-glucan in cell wall (FKS1 and FKS2) |

| **Rezafungin (CD101)**                        |
| Echinocandin - Non-competitive inhibition of 1,3-β-D-glucan synthase, depleting 1,3-β-D-glucan in cell wall (FKS1 and FKS2) |

| **Oteseconazole (VT-1161)**                   |
| Tetazole - Inhibition of lanosterol 14α-demethylese (ERG11, CYP51) |

**Figure 1.** Chemical structures, antifungal classes, and mechanisms of action of antifungals currently under late-stage clinical development, including manogepix, olorofim, ibrexafungerp, rezafungin, and oteseconazole.
Table 2. In vitro spectrum of activity of antifungals currently under late-stage clinical development, including manogepix, olorofim, ibrexafungerp, rezafungin, and oteseconazole. + = in vitro antifungal activity observed; − = no in vitro activity; blank cells = unknown.

| Antifungal | Manogepix | Olorofim | Ibrexafungerp | Rezafungin | Oteseconazole |
|------------|-----------|----------|---------------|-----------|--------------|
| Yeasts     |           |          |               |           |              |
| C. albicans| +         | −        | +             | +         | +            |
| C. auris   | +         | −        | +             | +         | +            |
| C. glabrata| +         | −        | +             | +         | +            |
| C. krusei  | −         | −        | +             | +         | +            |
| C. parapsilosis | +    | −        | +             | +         | +            |
| C. tropicalis| +   | −        | +             | +         | +            |
| C. gattii  | +         | −        | −             | −         | +            |
| C. neoformans| + | −        | −             | −         | +            |
| Rhodotorula| +         | −        | −             | −         | −            |
| Trichosporon | +/−| −        | −             | −         | −            |
| Aspergillus|           |          |               |           |              |
| A. flavus  | +         | +        | +             | +         | −            |
| A. fumigatus| +        | +        | +             | +         | −            |
| A. niger   | +         | +        | +             | +         | −            |
| A. terreus | +         | +        | +             | +         | −            |
| Fusarium   |           |          |               |           |              |
| F. oxysporum| +         | +/−      | −             | −         | −            |
| F. solani  | +         | −        | −             | −         | −            |
| Scedosporium|          |          |               |           |              |
| L. prolificans| +     | +        | −             | −         | −            |
| Mucorales  |           |          |               |           |              |
| Macor      | −         | −        | −             | −         | −            |
| Rhizopus   | +/−       | −        | −             | −         | +/−          |
| Other Mucorales| −     | −        | −             | −         | −            |
| Endemic Fungi|          |          |               |           |              |
| Blastomyces| +         | +        | −             | +         |              |
| Coccidioides| +        | +        | +             | +         |              |
| Histoplasma| +         | +        | −             | +         |              |
| Dermatophytes |       |          |               |           |              |
| Trichophyton| +         |          | −             | −         | +            |

2. Antifungals with Novel Mechanisms of Action
2.1. Manogepix
2.1.1. Mechanism of Action—Pharmacodynamics

Manogepix (APX001A) acts against fungi by inhibiting the fungal acyltransferase enzyme, Gwt1, which is an important component of the glycosylphosphatidylinositol (GPI)-anchored protein maturation pathway, and is essential for trafficking mannoproteins to the fungal cell membrane and wall [8,9]. GPI-anchored mannoproteins serve as adhesions, enabling fungi to adhere to mucosal epithelial surfaces within the host prior to colonization,
as well as infection [10]. Some fungal virulence factors are also derived from GPI-anchored proteins [10–14]. Thus, the inhibition of their synthesis may have pleotropic effects aside from growth inhibition. This agent was identified through a targeted search for agents that specifically inhibit Gwt1 and the optimization of identified leads [15]. Clinically, manogepix is administered as the N-phosphonooxymethyl prodrug, fosmanogepix (APX001), which is rapidly converted to manogepix by host phosphatases [15–17].

2.1.2. Spectrum of Activity and Resistance

Manogepix has broad-spectrum in vitro activity against fungi. Against yeasts, this includes activity against most Candida species, including C. albicans, C. auris, C. glabrata, C. parapsilosis, and C. tropicalis, as well as azole- and echinocandin-resistant strains [16–20], and Cryptococcus neoformans and C. gattii [21]. This in vitro activity has translated into efficacy in experimental models of candidiasis and cryptococciosis, including against infections caused by strains resistant to clinically available antifungals [20–23]. However, manogepix lacks or has limited activity against Candida krusei, C. inconspicua, and C. kefyr (Kluyveromyces marxianus). Activity has also been demonstrated against a limited number of Rhodotorula isolates, whereas its activity against Trichosporon asahii was variable [17].

Manogepix is also active against pathogenic molds, including Aspergillus, Fusarium, and Scedosporium species, as well as Lomentospora (Scedosporium) prolificans, a pathogen that is intrinsically resistant to clinically available antifungals [8,24–29]. Potent activity is also observed against strains of azole-resistant A. fumigatus. Similar to the echinocandins, manogepix does not necessarily inhibit the growth of filamentous fungi, but rather causes morphologic changes, which are observed in vitro as short, stubby, abnormally-branched hyphae, and the lowest concentration at which these occur is referred to as the MEC [15,30].

Reports of activity against different members of the order Mucorales have been mixed, with some studies showing no in vitro activity, but others reporting limited in vitro and in vivo activity against Rhizopus arrhizus [8,19,31]. A recent study reported that combination therapy with liposomal amphotericin B and fosmanogepix was superior to either agent alone against invasive aspergillosis, fusariosis, and mucormycosis [32].

Resistance to manogepix can develop due to point mutations that lead to amino acid substitutions within Gwt1 (i.e., V163A in C. glabrata and V162A in C. albicans) [33], and these changes do not affect the activity of other antifungals, such as the azoles and echinocandins. Interestingly, strains with elevated manogepix MICs that are wild-type for Gwt1 have also been reported to be cross-resistant to fluconazole. Although such cross-resistance has been attributed to efflux pumps due to marked increases in the transcription of efflux pump genes, such as CDR11, SNQ2, and MDR1 in C. albicans and MDR1 in C. parapsilosis [34], changes in manogepix and fluconazole MICs were minimal.

2.1.3. In Vivo Efficacy and Pharmacokinetics/Pharmacodynamics

The in vitro activity of manogepix has translated into in vivo efficacy in animal models of aspergillosis, fusariosis, scedoporiasis, coccidioidomycosis, and mucormycosis caused by Rhizopus arrhizus [24,27,31,35,36]. Interestingly, a recent study reported that combination therapy with liposomal amphotericin B and fosmanogepix was superior to either agent alone against invasive aspergillosis, fusariosis, and mucormycosis [32].

In experimental models of invasive candidiasis caused by C. albicans, C. glabrata, and C. auris, as well as invasive aspergillosis due to both wild-type and azole-resistant A. fumigatus, the pharmacokinetic/pharmacodynamic (PK/PD) parameters associated with manogepix efficacy were the AUC/MIC and AUC/MEC, respectively [20,23,35,37]. Against invasive candidiasis, the total free drug AUC/MIC (fAUC/MIC) ratios associated with stasis ranged from 1.35 to 22.54 [23]. Similarly, against invasive aspergillosis, the median fAUC/MEC associated with a 1-log reduction in fungal burden was 89.39 [35].
2.1.4. Tolerability and Drug Interactions

Manogepix appears to have fungal-specific activity, as it does not inhibit the human inositol acyltransferase, Pigw, at clinically relevant concentrations [38]. Administration of fosmanogepix has been safe and well-tolerated in Phase I and II clinical trials, with only mild adverse effects reported [39–42]. Clinically significant adverse effects and dose-limiting toxicities have not been observed. A Phase I drug–drug interaction study evaluating the effects of CYP3A4 and pan-CYP450 inhibition on fosmanogepix has been completed, but the results are not yet available [15]. However, the inhibition of CYP3A4 may potentially be of concern, as the non-selective CYP450 inhibitor, 1-aminobenzotriazole, has been utilized to improve the overall exposure profile of manogepix in mice due to rapid metabolism of this agent in this animal species [24,37,43].

2.2. Olorofim

2.2.1. Mechanism of Action—Pharmacodynamics

Olorofim (F901318, orotomide class) reversibly inhibits the dihydroorotate dehydrogenase (DHODH) enzyme, which is involved in the biosynthesis of pyrimidine [44]. This disruption leads to the loss of uridine-5′-monophosphate (UMP) and uridine-5′-triphosphate (UTP), which are important for the production of various cell wall components, as well as cytosine, thymine, and uracil, and also in cell cycle regulation [45]. Exposure of fungi to olorofim results in cell cycle arrest, as well as cell lysis [46,47]. Other effects have also been observed in Aspergillus following exposure to this agent, including inhibition of conidial germination; slowing of germ tube and hyphal growth; hyphal lysis; and, finally, cell death with prolonged exposure (120 h), suggesting that the effects of olorofim change from fungistatic to fungicidal with longer exposures [46]. Other effects of olorofim exposure include increases in hyphal septation, reductions in hyphal compartment sizes, and increased vacuolar volume, with the latter possibly indicating cell cycle arrest and a sign of autophagy [47,48]. This agent was identified through a screen of a library containing over 340,000 small molecules for in vitro activity specifically against Aspergillus fumigatus [44].

2.2.2. Spectrum of Activity and Mechanisms of Resistance

The spectrum of activity of olorofim is unique. It demonstrates potent activity against several pathogenic molds and dimorphic fungi, including Blastomyces, Coccidioides, and Histoplasma species, but it is devoid of activity against the Mucorales and yeasts, including Candida and Cryptococcus species [44,49–53]. In addition, the activity of olorofim is not uniform against all molds. For example, species-specific activity has been observed against Fusarium species, with the least activity observed against members of the Fusarium solani species complex [44,52]. This unique spectrum of activity of olorofim has been attributed to differences in the DHODH enzymes among various groups of fungi [44].

Despite the lack of activity against several important pathogen groups, olorofim has demonstrated promising activity against several fungi that either have reduced susceptibility or resistance to the extended spectrum azoles and amphotericin B. This includes azole-resistant Aspergillus fumigatus strains with CYP51A gene mutations, and cryptic Aspergillus species (e.g., A. calidosoestus, A. lentulus, A. tanneri, A. thermomutatus, and A. udagawa) with reduced azole susceptibility [44,53–55]. Olorofim is also active against several other molds that have reduced susceptibility or resistance to azoles and amphotericin B, including Scedosporium species, Lomentospora prolificans, and Microascus/Scopulariopsis species [44,49,51,52]. Other fungi that are inhibited by this agent include the hyaline molds, Paecilomyces variotii and Talaromyces marneffei, among others, and Madurella mycetomatis, the most common cause of eumycotic mycetoma [44,50,56].

Olorofim resistance can develop secondary to mutations within the gene encoding for DHODH. In a screen of 975 A. fumigatus isolates, no intrinsic resistance to this agent was found [57]. However, isolates with olorofim MICs of >8 mg/L could be selected in the laboratory with higher inocula and longer exposures to this agent. This was attributed to mutations within the PYRE gene leading to amino acid substitutions at locus G119 (i.e.,...
G119C and G119V) within DHODH, and a reduced affinity of olorofim for the mutated protein. Although fungi are capable of scavenging pyrimidine from the environment, the concentrations needed to reverse the in vitro effects of olorofim (≥5 mM) are markedly higher than what is found in human serum (~15 µM) [44]. Thus, the use of exogenous pyrimidine does not appear to be a mechanism by which fungi may become resistant to olorofim.

2.2.3. In Vivo Efficacy and Pharmacokinetics/Pharmacodynamics

Olorofim has also demonstrated in vivo effectiveness in several experimental models of invasive fungal infections, including invasive aspergillosis caused by different species of Aspergillus and azole-resistant A. fumigatus strains, central nervous system coccidioidomycosis, and disseminated scedosporiosis and lomentosporiosis [50,54,58–60]. The PK/PD parameter of olorofim associated with efficacy in experimental models of invasive mycoses has been the trough or Cmin/MIC. Against invasive aspergillosis caused by either azole-susceptible or resistant A. fumigatus strains, reductions in serum galactomannan levels and improvements in survival occurred with more frequent administration, and this time-dependent activity was confirmed by dose-fractionation studies [58]. A reduction in galactomannan of 27% was achieved with a Cmin/MIC range of 3 to 16.5 against 8 A. fumigatus challenge strains. These findings have been confirmed in other models of invasive mycoses, including sinopulmonary aspergillosis due to A. flavus, and coccidioidal meningitis caused by C. immitis [50,59], and is consistent with the time-dependent activity described in vitro [46].

2.2.4. Tolerability and Drug Interactions

Olorofim is significantly more potent against A. fumigatus DHODH (IC50 44 nM) compared to recombinant human DHODH (IC50 > 100 µM) [44], suggesting fungal-specific activity. In Phase I clinical studies, no significant changes in vital signs or laboratory values were reported, and no severe or serious adverse effects were observed in healthy subjects administered this agent [61,62]. Olorofim does undergo Phase I hepatic metabolism by several CYP450 enzymes [63], and it also acts as a weak inhibitor of CYP3A4 [64]. Thus, drug–drug interactions may be a clinical concern with this agent.

2.3. Other Antifungals with Novel Mechanisms of Action

Other antifungals with novel mechanisms of action that are not yet at advanced stages of clinical development include ATI-2307 and GR-2307. ATI-2307 (formerly T-2307) is an aromatic diamidine with a structure similar to pentamidine that was identified in a screen of specific compounds in the chemical library at Toyama Chemical Company [65]. This agent causes the collapse of fungal mitochondrial membrane potential by inhibiting the respiratory chain complex, resulting in decreased adenosine triphosphate levels [66–68]. ATI-2307 has in vitro activity against Candida species, including azole and echinocandin-resistant strains of C. albicans, C. glabrata, and C. auris, Cryptococcus species, Malassezia furfur, Aspergillus species, Fusarium solani, and Lichtheimia corymbifera [65,69–72]. In vivo efficacy has also been reported in animal models of invasive candidiasis, cryptococcosis, and aspergillosis [65,70,71,73,74]. However, reduced to no activity has been reported against Rhizopus arrhizus, Mucor racemosus, Scedosporium species, Trichophyton rubrum, and Trichosporon asahii.

GR-2397, formerly VL-2397 and ASP2397, is a cyclic hexapeptide originally isolated from an Acremonium persicinum strain (MF-34833) as part of a program to discover new agents for pulmonary aspergillosis [75]. Although the intracellular drug target is unknown, GR-2397 is structurally related to the siderophore, ferrichrome, and this agent is taken up into A. fumigatus cells by the siderophore transporter, Sit1 [76]. Thus, the antifungal activity is observed against species in which Sit1 is present [63,77], such as C. glabrata, including echinocandin- and azole-resistant strains, and C. kefyr, but not C. albicans [76–78]. Activity has also been demonstrated against Aspergillus species, including azole-susceptible and
resistant *A. fumigatus* strains, *A. flavus*, and *A. terreus* [76,79]. In experimental models of invasive candidiasis, efficacy has been demonstrated against infections caused by both wild-type and azole- and echinocandin-resistant *C. glabrata* isolates [78]. Efficacy has also been reported against aspergillosis [76], and the limited PK/PD data that are available suggest that AUC/MIC is the parameter most closely associated with in vivo efficacy, as this was demonstrated in a murine model of invasive pulmonary aspergillosis [80].

3. New Antifungals That Improve upon Current Classes and Mechanisms of Action

3.1. *Ibrexafungerp*

3.1.1. Mechanism of Action—Pharmacodynamics

*Ibrexafungerp* (SCY-078, triterpenoid class) is a semi-synthetic compound derived from the natural product, enfumafungin [81]. Similar to the echinocandins, ibrexafungerp inhibits the production of 1,3-β-D-glucan through non-competitive inhibition of the 1,3-β-D-glucan synthase complex [82,83], although it is structurally different and not a member of this class. Inhibition of 1,3-β-D-glucan synthesis weakens the cell wall, and results in osmotic instability and eventual cell lysis [82,84]. However, the binding sites for ibrexafungerp and the echinocandins only partially overlap; thus, cross-resistance between these different antifungal classes is limited [85–87]. Unlike the echinocandins, ibrexafungerp can be absorbed from the gastrointestinal tract following oral administration, and does not have to be administered intravenously.

3.1.2. Spectrum of Activity and Mechanisms of Resistance

*Ibrexafungerp* has in vitro activity against several *Candida* species, including *C. albicans*, *C. glabrata*, *C. parapsilosis*, and *C. tropicalis*, as well as the emerging pathogen, *C. auris* [88]; against which, antibiofilm activity has also been demonstrated [89,90]. Its activity is also maintained against azole-resistant isolates. However, reduced potency has been reported against *C. lusitaniae* and *C. krusei*. Unlike the azoles, the activity of ibrexafungerp against *Candida* species is maintained in low pH environments [91–93], which may make it useful for the treatment of vulvovaginal candidiasis, for which it has received regulatory approval for clinical use in the U.S.

*Ibrexafungerp* also demonstrates activity against *Aspergillus* species, including *A. fumigatus*, *A. niger*, and *A. terreus*, as well as cryptic species and strains that are azole-resistant [83,85,94,95]. In a rabbit model of invasive aspergillosis, enhanced efficacy, as measured by reductions in pulmonary injury, fungal burden, galactomannan and 1,3-β-D-glucan levels, and improvements in survival, was observed when ibrexafungerp was combined with isavuconazole [96]. However, ibrexafungerp lacks in vitro activity against the Mucorales and *Fusarium* species, and has variable activity against other molds, including *Microascus/Scopulariopsis* species, *Purpureocillium lilacinum*, and *Scedosporium* species [97]. The in vitro activity of ibrexafungerp and the echinocandins against molds is measured as the MEC value, which, as described above for manogepix, is the lowest concentration that results in morphologic changes (i.e., short, stubby, abnormally-branched hyphae) [30]. These changes are due to the location of the 1,3-β-D-glucan synthase enzymes at the apical tips and branch points of hyphae where growth occurs [30,82].

Point mutations within the *FKS1* and *FKS2* genes that encode subunits of 1,3-β-D-glucan synthase can lead to ibrexafungerp and echinocandin resistance [98]. As noted previously, the binding sites for ibrexafungerp and the echinocandins only partially overlap. Thus, the activity of ibrexafungerp against *Candida* strains harboring *FKS* mutations is variable [87,99], although it is generally more potent against *FKS* mutants compared to the echinocandins [99–102]. However, *FKS* mutations that lead to specific amino acid changes, such as F641S in *C. albicans*, and F649del, F658del, F659S, F659del, E655A, and W715L in *C. glabrata*, can reduce ibrexafungerp activity [95,103–106].
3.1.3. In Vivo Efficacy and Pharmacokinetics/Pharmacodynamics

Consistent with its in vitro activity, several studies have reported ibrexafungerp to have in vivo efficacy in experimental models in candidiasis caused by different Candida species, including C. albicans, C. glabrata, C. tropicalis, and C. auris [107,108]. Ibrexafungerp has also demonstrated prophylactic activity in a murine model against Pneumocystis pneumonia due to its activity against the cyst form of this organism [109]. From a PK/PD standpoint, the AUC/MIC has correlated with the effectiveness of ibrexafungerp in animal models of invasive candidiasis [107,110]. When assessed by overall exposure, the ibrexafungerp free drug AUC/MIC (fAUC/MIC) ratios associated with stasis, and measured by reductions in kidney fungal burden, have ranged from 0.1 to 1.7, and these were lower to those reported for the echinocandins [107,110,111]. This difference may be due to higher concentrations of ibrexafungerp within the kidneys due to extensive tissue distribution [110]. Fungicidal activity, defined as a 1-log reduction in fungal burden, has been reported with ibrexafungerp fAUC/MIC ratios of 0.91 to 1.42 [107]. The estimated protein-binding of ibrexafungerp ranges between 99.5% and 99.8% [110]. Although the PK/PD parameter of ibrexafungerp has not been formally defined against Aspergillus infections, it is thought to be the AUC/MEC [112].

3.1.4. Tolerability and Drug Interactions

In Phase I and II clinical studies, ibrexafungerp has been well-tolerated, although non-serious adverse effects did increase with higher doses and longer durations of therapy [113]. The most common mild-to-moderate adverse effects included nausea, vomiting, diarrhea, and abdominal pain [112,114,115]. Of note, prolongations in QTc intervals were not observed in a Phase II study of patients with invasive candidiasis [115]. Ibrexafungerp is metabolized by CYP3A4, and the coadministration of strong inducers, such as rifampin, or inhibitors of this enzyme, including itraconazole, should be avoided, as these may lead to insufficient or supratherapeutic ibrexafungerp concentrations, respectively. Ibrexafungerp is also a reversible inhibitor of CYP2C8 and 3A4. However, the coadministration of ibrexafungerp and rosiglitazone, which is metabolized by CYP2C8, had no effect on the overall exposure of this anti-diabetic drug [116]. Similarly, only a modest increase in tacrolimus concentrations, which is metabolized by CYP3A4, were observed with the co-administration of ibrexafungerp [112]. Although tacrolimus dose adjustments are not currently recommended when co-administered with ibrexafungerp, levels of this calcineurin inhibitor should be monitored.

3.2. Rezafungin

3.2.1. Mechanism of Action—Pharmacodynamics

Rezafungin (CD101) is a second-generation echinocandin, and, similar to other echinocandins, causes non-competitive inhibition of the 1,3-β-D-glucan synthase enzyme complex [117]. 1,3-β-D-glucan is a major cell wall component of many pathogenic fungi; thus, inhibiting its synthesis results in osmotic instability and eventual cell lysis [82,84]. Rezafungin is similar to anidulafungin in structure, but is modified within the cyclic core, having the ornithine hemiaminal replaced with a choline aminal ether [118]. This change leads to greater stability and a prolonged half-life for rezafungin (~130 h vs. ~24 h for anidulafungin) [118–122].

3.2.2. Spectrum of Activity and Mechanisms of Resistance

As with the other echinocandins, rezafungin has potent in vitro activity against Candida and Aspergillus species. This includes Candida species that frequently cause infections in humans, such as C. albicans, C. glabrata, C. tropicalis, and C. krusei, as well as less common species, including C. dubliniensis, C. fabianii, C. inconspicua, C. kefyr, C. lipolytica, and C. lusitaniae, among others [123–126]. Potent activity has also been observed against C. auris [126]. Reduced potency is observed against members of the C. parapsilosis species complex, including C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis, as well
as against *C. guilliermondii* [125,126]. Rezafungin also lacks activity against fungi that are intrinsically resistant to the echinocandin class, including *Cryptococcus, Rhodotorula,* and *Trichosporon* species [117,124]. Rezafungin does have activity against *Aspergillus fumigatus,* including azole-resistant isolates, *A. flavus,* *A. terreus,* and *A. niger.* It is also active against cryptic members of *Aspergillus* section *Fumigati* (e.g., *A. lentulus,* *A. thermomutatus,* and *A. udagawae*), and *A. calidoustus* [123,127]. As with the other echinocandins, the in vitro activity of rezafungin against molds is measured as the MEC and not the MIC. Resistance to the echinocandins is caused by mutations within highly conserved regions (hot spots 1 and 2) of *FKS1* and *FKS2* genes that encode subunits of the 1,3-β-D-glucan synthase complex [98]. In fact, the reduced activity of this class against members of the *C. parapsilosis* species complex and *C. guilliermondii* is due to naturally occurring point mutations within *FKS1* [128,129]. Against *Candida* isolates harboring *FKS* mutations, rezafungin MICs have been reported to be similar to those of other echinocandins [124,130].

### 3.2.3. In Vivo Efficacy and Pharmacokinetics/Pharmacodynamics

In vivo efficacy has also been reported against infections caused by *Candida* and *Aspergillus* species. Experimental models of invasive candidiasis have demonstrated rezafungin to be effective against infections caused by several *Candida* species, including *C. albicans,* *C. auris,* *C. dubliniensis,* *C. glabrata,* *C. parapsilosis,* and *C. tropicalis* [23,131–135]. Although its in vitro activity appears to be similarly affected by *FKS* mutations in a similar fashion as the other echinocandins, in one study, rezafungin maintained in vivo efficacy against infection caused by a *C. albicans* isolate harboring a heterozygous *FKS* mutant at codon S645, despite reduced in vitro activity against this strain [135]. Rezafungin was also effective in a rabbit model for the treatment of endophthalmitis caused by wild-type *C. albicans* [136]. In experimental models of invasive aspergillosis caused by *A. fumigatus,* rezafungin was also effective against infections caused by wild-type and azole-resistant strains [137,138]. Prophylactic efficacy has also been demonstrated against *Pneumocystis pneumonia,* as rezafungin was effective in blocking the formation of the reproductive forms of *P. murina* in immunocompromised mice [139].

As with the other echinocandins, the PK/PD parameter associated with rezafungin efficacy is the AUC/MIC. In neutropenic murine models of invasive candidiasis caused by *C. albicans,* *C. glabrata,* and *C. parapsilosis* strains with varying echinocandin susceptibility profiles, free drug AUC/MIC ratios associated with fungal burden stasis ranged from 0.07 to 2.92, whereas 1-log reductions in fungal burden were two- to four-fold higher [131]. Similarly, in murine models of candidiasis caused by *C. auris,* *C. dubliniensis,* and *C. tropicalis,* free drug AUC/MIC ratios associated with stasis ranged from 1.88 to 11.65, and those associated with at least a 1-log reduction in fungal burden were also approximately two- to four-fold higher [131,132]. Dose fractionation studies in mice have also demonstrated that the shape of the concentration–time curve is important against *Candida* infections, as single high doses were associated with the largest decreases in fungal burden compared to the same overall doses administered more frequently [140]. The Cmax/MEC ratio has been reported to be associated with efficacy for the echinocandins against *A. fumigatus* infections [141], and extended-interval dosing of rezafungin was associated with improved survival and reductions in fungal burden in a murine model of disseminated aspergillosis caused by an *A. fumigatus* isolate harboring a TR34/L98H mutation in CYP51A [138].

### 3.2.4. Tolerability and Drug Interactions

Due to the fungal-specific mechanism of action of the echinocandins, this class is very well-tolerated. In healthy volunteers, the majority of adverse effects were mild and transient. There was a tendency towards higher rates of adverse effects, such as infusion reactions, in the group that received the highest rezafungin dose [121]. In addition, no ECG abnormalities, including prolongations the QTc interval, were reported with rezafungin infusions up to 1400 mg [142]. Similarly, in Phase II studies, rezafungin was safe and well-tolerated in patients with candidemia and invasive candidiasis, and treatment-emergent
adverse effects were deemed to be mild to moderate [143]. Rezafungin has a low potential for drug–drug interactions, and minimal interactions with recombinant CYP450 enzymes have been observed in vitro [144].

3.3. Oteseconazole

3.3.1. Mechanism of Action—Pharmacodynamics

To overcome drug–drug interactions that limit the clinical utility of triazoles, oteseconazole (VT-1161) and similar compounds (e.g., VT-1129 and VT-1598) have been designed to have greater specificity for the fungal Cyp51 enzyme (i.e., lanosterol 14α-demethylase). In oteseconazole, the triazole iron-binding group has been replaced with a tetrazole (i.e., four nitrogen atoms in the five-member ring), and the portion of the molecule recognized by amino acids of the substrate-binding site within Cyp51 has also been modified [145]. Studies have reported a greater affinity of oteseconazole for fungal Cyp51 compared to human CYP450 enzymes (~2000-fold) [145–148]. Thus, oteseconazole’s mechanism of action is the same as the triazoles (i.e., inhibition of ergosterol biosynthesis), but with greater selectivity for fungal enzymes and potentially fewer adverse effects and drug–drug interactions.

3.3.2. Spectrum of Activity and Mechanisms of Resistance

Oteseconazole is active against Candida species, including fluconazole-susceptible and resistant isolates, Cryptococcus neoformans, Coccidioides immitis/posadasii, and Trichophyton species [148–153].

Resistance to oteseconazole can occur by some of the same mechanisms that cause resistance to the triazoles. In Candida albicans, marked increases in oteseconazole MICs were reported to be caused by different mechanisms, including a premature stop codon in the ERG3 gene; amino acid substitutions within the Erg11 enzyme; and overexpression of the ATP-binding cassette transporter genes, CDR1 and MDR1 [152,154]. Similarly, in C. glabrata, the efflux pump, Cdr1p, appears to affect oteseconazole activity to a greater extent than that of Pdh1 and Snq2, all of which are regulated by the zinc cluster transcription factor, Pdr1 [151]. Oteseconazole activity was also affected by Upc2a, another zinc cluster transcription factor that regulates the genes involved in ergosterol biosynthesis.

3.3.3. In Vivo Efficacy and Pharmacokinetics/Pharmacodynamics

Efficacy has also been reported in animal models of various mycoses, including oropharyngeal and vulvovaginal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans strains, and onychomycosis [155–157]. Reductions in fungal burden and improvements in survival were also reported with oteseconazole treatment in experimental models of coccidioidomycosis [149,158]. Prophylactic efficacy has also been demonstrated in a murine model of pulmonary mucormycosis caused by Rhizopus arrhizus var. arrhizus, which is consistent with the in vitro activity demonstrated against this species [159].

Although the PK/PD profile of oteseconazole most closely associated with efficacy has not been formally studied, it is likely to be similar to the azoles, which is the AUC/MIC. Given that the half-life reported in humans is 138 days, good exposures are expected [160,161]. Long half-lives leading to sustained plasma levels and exposures have been observed in various animals [149,158,161], and in a guinea pig model of onychomycosis, efficacy was observed with either once-daily or once-weekly dosing [156]. Oteseconazole was recently approved by the U.S. Food and Drug Administration for the treatment of recurrent vulvovaginal candidiasis, and is recommended to be given orally at doses of 600 mg on day 1; 450 mg on day 2; and then, beginning on day 14, 150 mg once-weekly when used as monotherapy [160].

3.3.4. Tolerability and Drug Interactions

Oteseconazole has been well-tolerated in clinical trials, with the most frequently reported adverse effects being headache and nausea [160–164]. Most adverse effects were mild to moderate, and were judged to be unrelated to the study drug. Oteseconazole does not undergo significant metabolism, and co-administration with other drugs that are
metabolized by CYP3A4 (midazolam, ethinyl estradiol, norethindrone) or are substrates of p-glycoprotein (digoxin) did not result in significant differences in the pharmacokinetics of these agents [160]. These results are consistent with oteseconazole having greater selectivity for fungal Cyp51 compared to mammalian CYP450 enzymes.

4. New Routes of Administration

In addition to new classes of antifungals with novel mechanisms of action and modifications to established classes, new formulations of antifungals within established classes that have different routes of administration are also being developed, including otepconazole and encochleate amphotericin B (MAT2203). Opetconazole (PC945) is a triazole under development for administration directly to the lungs via inhalation, thus possibly limiting systemic exposure [165]. Thus, it may reach high pulmonary concentrations at the site of infection of fungi while possibly avoiding drug–drug interactions and adverse effects that occur primarily within the liver. Opetconazole has broad-spectrum activity against *Candida* species, including *C. albicans*, *C. glabrata*, *C. krusei*, and *C. auris*; *Cryptococcus* species; several *Aspergillus* species, including *A. fumigatus* and *A. flavus*; and *Rhizopus arrhizus* [166]. However, it lacks activity against other fungal pathogens, including *A. niger*, *Lichtheimia corymbifera*, and certain *Penicillium* species (i.e., *P. chrysogenum* and *P. citrinum*). Studies in humans have been limited, but otepconazole has been well-tolerated following inhaled administration to healthy individuals and those with mild asthma [165].

MAT2203 is a nanoparticle-based, encochleated formulation of amphotericin B that is under development for oral administration of this polyene. As with other amphotericin B formulations, MAT2203 binds to ergosterol within the fungal cell membrane, leading to membrane disruption. Amphotericin B has broad-spectrum activity, and MAT2203 was reported to have dose-dependent activity in different organs in a murine model of systemic candidiasis [167]. In humans, measurable bloodstream concentrations have been reported following oral administration of MAT2203, and the agent was well-tolerated at doses up to 800 mg/day [168].

5. Conclusions

Currently, there are several antifungals in development for the treatment of invasive mycoses, with some in late-stage clinical trials. These include agents within new classes with novel mechanisms of action and pharmacodynamics (i.e., manogepix, olorofim, ATI-2307, and GR-2397) that demonstrate in vitro and in vivo activity against strains that have developed resistance to azoles and the echinocandins, as well as species that are intrinsically resistant to most clinically available antifungals. Others include those with the same or similar mechanisms of action of clinically available antifungals, but that have been modified to improve their pharmacokinetic profile (i.e., rezafungin), allow for oral administration (i.e., ibrexafungerp, MAT2203), are delivered directly to the lungs (otepconazole), or have reduced potential for clinically significant drug–drug interactions and adverse effects (i.e., oteseconazole). Each of these agents has the potential to improve clinical outcomes and expand options available to clinicians for the treatment of invasive mycoses.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** N.P.W. has received research support from Astellas, bioMerieux, F2G, Maxwell Biosciences, Mycovia, and Sfunga.
25. Castanheira, M.; Duncanson, F.P.; Diekema, D.J.; Guarro, J.; Jones, R.N.; Pfaller, M.A. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. *Antimicrob. Agents Chemother.* 2012, 56, 352–357. [CrossRef] [PubMed]

26. Gebremariam, T.; Alkhazraji, S.; Alqarihi, A.; Jeon, H.H.; Gu, Y.; Kapoor, M.; Shaw, K.; Ibrahim, A.S. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. *Antimicrob. Agents Chemother.* 2019, 63, e01713-18. [CrossRef]

27. Hata, K.; Horii, T.; Miyazaki, M.; Watanabe, N.A.; Okubo, M.; Sonoda, J.; Nakamoto, K.; Tanaka, K.; Shirotori, S.; Murai, N.; et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. *Antimicrob. Agents Chemother.* 2011, 55, 4543–4551. [CrossRef]

28. Jorgensen, K.M.; Astvd, K.M.T.; Arendrup, M.C. In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination. *Antimicrob. Agents Chemother.* 2020, 64, e00730-20. [CrossRef]

29. Pfaffer, M.A.; Duncanson, F.; Messer, S.A.; Moet, G.J.; Jones, R.N.; Castanheira, M. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against *Aspergillus* spp. determined by CLSI and EUCAST broth microdilution methods. *Antimicrob. Agents Chemother.* 2011, 55, 5155–5158. [CrossRef]

30. Aritani, S.; Lozano-Chiu, M.; Paetzstzick, V.; Rex, J.H. In vitro susceptibility testing methods for caspofungin against *Aspergillus* and Fusarium isolates. *Antimicrob. Agents Chemother.* 2001, 45, 327–330. [CrossRef]

31. Gebremariam, T.; Alkhazraji, S.; Alqarihi, A.; Wiederhold, N.P.; Shaw, K.J.; Patterson, T.F.; Filler, S.G.; Ibrahim, A.S. Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to *Rhizopus arrhizus*. *Antimicrob. Agents Chemother.* 2020, 64, e00178-20. [CrossRef]

32. Gebremariam, T.; Gu, Y.; Alkhazraji, S.; Youssef, E.; Shaw, K.J.; Ibrahim, A.S. The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B is Superior to Monotherapy in Treating Experimental Molds Infections. *Antimicrob. Agents Chemother.* 2022, 66, e00390-22. [CrossRef]

33. Kapoor, M.; Moloney, M.; Soltow, Q.A.; Pillar, C.M.; Shaw, K.J. Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species. *Antimicrob. Agents Chemother.* 2019, 64, e01387-19. [CrossRef] [PubMed]

34. Liston, S.D.; Whitesell, L.; Kapoor, M.; Shaw, K.J.; Cowen, L.E. Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility. *Antimicrob. Agents Chemother.* 2020, 64, e00261-20. [CrossRef] [PubMed]

35. Zhao, M.; Lepak, A.J.; Marchillo, K.; Vanhecker, J.; Sanchez, H.; Ambrose, P.G.; Andes, D.R. APX001 Pharmacokinetic/Pharmacodynamic Target Determination against *Aspergillus fumigatus* in an In Vivo Model of Invasive Pulmonary Aspergillosis. *Antimicrob. Agents Chemother.* 2019, 63, e02372-18. [CrossRef] [PubMed]

36. Viriyakosol, S.; Kapoor, M.; Okamoto, S.; Covel, J.; Soltow, Q.A.; Trzoss, M.; Shaw, K.J.; Fierer, J. APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccioidioides immitis Pneumonia. *Antimicrob. Agents Chemother.* 2019, 63, e01715-18. [CrossRef] [PubMed]

37. Zhao, Y.; Lee, M.H.; Paderu, P.; Lee, A.; Jimenez-Ortigosa, C.; Park, S.; Mansbach, R.S.; Shaw, K.J.; Perlin, D.S. Significantly Improved Pharmacokinetics Enhance In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis. *Antimicrob. Agents Chemother.* 2018, 62, e00425-18. [CrossRef] [PubMed]

38. Watanabe, N.A.; Miyazaki, M.; Horii, T.; Sagane, K.; Tsukahara, K.; Hata, K. E1210, a new broad-spectrum antifungal, suppresses *Candida albicans* hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. *Antimicrob. Agents Chemother.* 2012, 56, 960–971. [CrossRef] [PubMed]

39. Hodges, M.R.; Ople, E.; Shaw, K.J.; Mansbach, R.; Van Hoogdalem, E.; Wedel, P. Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. Open Forum Infect. Dis. 2017, 4, S534. [CrossRef]

40. Hodges, M.R.; Ople, E.; Shaw, K.J.; Mansbach, R.; Van Hoogdalem, E.; Wedel, P.; Kramer, W. First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. *Open Forum Infect. Dis.* 2017, 4, S526. [CrossRef]

41. Pappas, P.G.; Kullberg, B.J.; Vazquez, J.A.; Oren, I.; Rahav, G.; Aoun, M.; Bulpa, P.; Ben-Ami, R.; Ferrer, R.; McCarty, T.; et al. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial. Presented at the Programs and Abstracts of the 55th Annual Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA, USA, 21–25 October 2020. IDWeek 2020.

42. Bulpa, P.; Rahav, G.; Oren, I.; Aoun, M.; Thompson, G.R., 3rd; Pappas, P.G.; Kullberg, B.J.; Vazquez, J.A.; Barbat, S.H.; Wedel, P.; et al. Clinical Safety and Efficacy of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial. In Proceedings of the Programs and Abstracts of the 55th Annual Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA, USA, 21–25 October 2020. IDWeek 2020.

43. Balani, S.K.; Zhu, T.; Yang, T.J.; Liu, Z.; He, B.; Lee, F.W. Effective dosing regimen of 1-amino-benzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. *Drug Metab. Dispos.* 2002, 30, 1059–1062. [CrossRef]

44. Oliver, J.D.; Sibley, G.E.; Beckmann, N.; Dobb, K.S.; Slater, M.J.; McEntee, L.; du Pre, S.; Livermore, J.; Bromley, M.J.; Wiederhold, N.P.; et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. *Proc. Natl. Acad. Sci. USA* 2016, 113, 12809–12814. [CrossRef]

45. Gow, N.A.R.; Latge, J.P.; Munro, C.A. The Fungal Cell Wall: Structure, Biosynthesis, and Function. *Microbiol. Spectr.* 2017, 5. [CrossRef] [PubMed]
46. du Pre, S.; Beckmann, N.; Almeida, M.C.; Sibley, G.E.M.; Law, D.; Brand, A.C.; Birch, M.; Read, N.D.; Oliver, J.D. Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob. Agents Chemother. 2018, 62, e00231-18. [CrossRef] [PubMed]

47. du Pre, S.; Birch, M.; Law, D.; Beckmann, N.; Sibley, G.E.M.; Bromley, M.J.; Read, N.D.; Oliver, J.D. The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus. J. Fungi 2020, 6, 47. [CrossRef] [PubMed]

48. Wiederhold, N.P. Review of the Novel Investigational Antifungal Olorofim. J. Fungi 2020, 6, 122. [CrossRef]

49. Wiederhold, N.P.; Law, D.; Birch, M. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. J. Antimicrob. Chemother. 2017, 72, 1977–1980. [CrossRef]

50. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Birch, M.; Law, D.; Rex, J.H.; Catano, G.; Patterson, T.F. The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. Antimicrob. Agents Chemother. 2018, 62, e00999-18. [CrossRef]

51. Biswas, C.; Law, D.; Birch, M.; Halliday, C.; Sorrell, T.C.; Rex, J.; Slavin, M.; Chen, S.C. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med. Mycol. 2018, 56, 1050–1054. [CrossRef]

52. Jorgensen, K.M.; Astvad, K.M.T.; Hare, R.K.; Arendrup, M.C. EUCAST Determination of Olorofim (F901318) Susceptibility of Cryptococcus neoformans, Candida albicans, and Candida parapsilosis. Antimicrob. Agents Chemother. 2018, 62, e00487-18. [CrossRef]

53. Rivero-Menendez, O.; Cuenca-Estrella, M.; Alastruey-Izquierdo, A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J. Antimicrob. Chemother. 2019, 74, 1586–1590. [CrossRef]

54. Seyedmousavi, S.; Chang, Y.C.; Law, D.; Birch, M.; Rex, J.H.; Kwon-Chung, K.J. Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. Antimicrob. Agents Chemother. 2019, 63, e0129-19. [CrossRef]

55. Buil, J.B.; Rijs, A.; Meis, J.F.; Birch, M.; Law, D.; Melchers, W.J.G.; Verweij, P.E. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J. Antimicrob. Chemother. 2017, 72, 2548–2552. [CrossRef] [PubMed]

56. Lim, W.; Eadie, K.; Konings, M.; Rijnbers, B.; Fahal, A.H.; Oliver, J.D.; Birch, M.; Verbon, A.; van de Sande, W. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. J. Antimicrob. Chemother. 2020, 75, 936–941. [CrossRef] [PubMed]

57. Buil, J.B.; Oliver, J.D.; Law, D.; Baltussen, T.; Zoll, J.; Hokken, M.W.J.; Melchers, W.J.G.; Birch, M.; Verweij, P.E. Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance. Emerg. Microbes Infect. 2022, 11, 703–714. [CrossRef] [PubMed]

58. Hope, W.W.; McEntee, L.; Livermore, J.; Whalley, S.; Johnson, A.; Farrington, N.; Kolamunnage-Dona, R.; Schwartz, J.; Kennedy, A.; Law, D.; et al. Pharmacodynamics of the Orotamides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. mBio 2017, 8, e01157-17. [CrossRef]

59. Negri, C.E.; Johnson, A.; McEntee, L.; Box, H.; Whalley, S.; Schwartz, J.A.; Ramos-Martín, V.; Livermore, J.; Kolamunnage-Dona, R.; Colombo, A.L.; et al. Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus fumigatus. J. Infect. Dis. 2018, 217, 1118–1127. [CrossRef]

60. Seyedmousavi, S.; Chang, Y.C.; Youn, J.H.; Law, D.; Birch, M.; Rex, J.H.; Kwon-Chung, K.J. In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis. Antimicrob. Agents Chemother. 2021, 65, e003421. [CrossRef]

61. Kennedy, T.; Allen, G.; Steiner, J.; Heep, M.; Birch, M. Assessment of the duration of infusion on the tolerability and repeat dose pharmacokinetics of F901318 in healthy volunteers (abstr. P1711). In Proceedings of the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.

62. Kennedy, T.; Allen, G.; Steiner, J.; Heep, M.; Sibley, G.; Law, D.; Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects (abstr. P1710). In Proceedings of the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.

63. Rauseo, A.M.; Coler-Reilly, A.; Larson, L.; Spec, A. Hope on the Horizon: Novel Fungal Treatments in Development. Open Forum Infect. Dis. 2020, 7, ofaa016. [CrossRef]

64. Kennedy, T.; Allen, G.; Steiner, J.; Oliver, J.; Birch, M.; Law, D. An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe (abstr. P1737). In Proceedings of the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.

65. Mitsuayama, J.; Nomura, N.; Hashimoto, K.; Yamada, E.; Nishihara, H.; Kaeriya, M.; Kimura, A.; Todo, Y.; Narita, H. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemother. 2008, 52, 1318–1324. [CrossRef]

66. Lanteri, C.A.; Trumpower, B.L.; Tidwell, R.R.; Meshnick, S.R. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 2004, 48, 3968–3974. [CrossRef]

67. Yamada, E.; Nishihara, H.; Nomura, N.; Mitsuayama, J. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob. Agents Chemother. 2010, 54, 3630–3634. [CrossRef]

68. Yamashita, K.; Miyazaki, T.; Fukuda, Y.; Mitsuayama, J.; Saijo, T.; Shimamura, S.; Yamamoto, K.; Imamura, Y.; Izumi-Kawase, K.; Yanagi-Hara, K.; et al. The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes. Antimicrob. Agents Chemother. 2019, 63, e00374-19. [CrossRef] [PubMed]
69. Wiederhold, N.P.; Najjar, L.K.; Jaramillo, R.; Olivo, M.; Patterson, H.; Connell, A.; Fukuda, Y.; Mitsuyama, J.; Catano, G.; Patterson, T.F. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris. *Antimicrob. Agents Chemother.* 2020, 64, e02198-19. [CrossRef] [PubMed]

70. Wiederhold, N.P.; Najjar, L.K.; Fothergill, A.W.; Bocanegra, R.; Olivo, M.; McCarthy, D.I.; Fukuda, Y.; Mitsuyama, J.; Patterson, T.F. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. *J. Antimicrob. Chemother.* 2016, 71, 692–695. [CrossRef]

71. Wiederhold, N.P.; Najjar, L.K.; Fothergill, A.W.; Bocanegra, R.; Olivo, M.; McCarthy, D.I.; Kirkpatrick, W.R.; Fukuda, Y.; Mitsuyama, J.; Patterson, T.F. The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans. *Antimicrob. Agents Chemother.* 2015, 59, 1341–1343. [CrossRef]

72. Dietl, A.M.; Misslinger, M.; Aguiar, M.M.; Ivashov, V.; Teis, D.; Pfister, J.; Decristofoforo, C.; Hermann, M.; Sullivan, S.M.; Smith, L.R.; et al. The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397. *Antimicrob. Agents Chemother.* 2018, 63, e00807-19. [CrossRef]

73. Nakamura, I.; Yoshimura, S.; Masaki, T.; Takase, S.; Ohsumi, K.; Hashimoto, M.; Furukawa, S.; Fujie, A. ASP2397: A novel antifungal agent produced by Acremonium persicinum MF-347833. *J. Antibi. 2017, 70, 45–51.* [CrossRef]

74. Rubino, C.M.; Smith, L.R.; Mammen, M.P.; Hopkins, A.M.; Lakota, E.A.; Sullivan, S.M. Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis. *Open Forum Infect. Dis.* 2017, 4, S473. [CrossRef]

75. Østergaard, C.; Jensen, R.H.; Cuenca-Estrella, M. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms. *Antimicrob. Agents Chemother.* 2016, 60, 532–536. [CrossRef] [PubMed]

76. Nakamura, I.; Ohsumi, K.; Takeda, S.; Katsumata, K.; Matsumoto, S.; Akamatsu, S.; Mitori, H.; Nakai, T. ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter. *Antimicrob. Agents Chemother.* 2019, 63, e02689-18. [CrossRef]

77. Abe, M.; Nakamura, S.; Kinjo, Y.; Masuyama, Y.; Mitsuyama, J.; Kaku, M.; Miyazaki, Y.; et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: An emerging fungal pathogen. *J. Antimicrob. Chemother.* 2017, 72, 1709–1713. [CrossRef] [PubMed]

78. Wiederhold, N.P.; Najjar, L.K.; Bocanegra, R.; Kirkpatrick, W.R.; Patterson, T.F. Comparison of anidulafungin’s and fluconazole’s in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. *Clin. Microbiol. Infect.* 2012, 18, E20–E23. [CrossRef]

79. Dietl, A.M.; Misslinger, M.; Aguiar, M.M.; Ivashov, V.; Teis, D.; Pfister, J.; Decristofoforo, C.; Hermann, M.; Sullivan, S.M.; Smith, L.R.; et al. The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397. *Antimicrob. Agents Chemother.* 2019, 63, e00807-19. [CrossRef]

80. Bowman, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. *Antimicrob. Agents Chemother.* 2002, 46, 3001–3012. [CrossRef]

81. Morgan, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. *Antimicrob. Agents Chemother.* 1997, 41, 247–2479. [CrossRef]

82. Bowman, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. *Antimicrob. Agents Chemother.* 2002, 46, 3001–3012. [CrossRef]

83. Wiederhold, N.P. The antifungal arsenal: Alternative drugs and future targets. *Int. J. Antimicrob. Agents 2018, 51, 333–339. [CrossRef] [PubMed]

84. Wiederhold, N.P.; Najjar, L.K.; Jaramillo, R.; Olivo, M.; Patterson, H.; Connell, A.; Fukuda, Y.; Mitsuyama, J.; Catano, G.; Patterson, T.F. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris. *Antimicrob. Agents Chemother.* 2020, 64, e02198-19. [CrossRef] [PubMed]

85. Rubino, C.M.; Smith, L.R.; Mannen, M.P.; Hopkins, A.M.; Lakota, E.A.; Sullivan, S.M. Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis. *Open Forum Infect. Dis.* 2017, 4, S473. [CrossRef]

86. Arendrup, M.C.; Jensen, R.H.; Cuenca-Estrella, M. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms. *Antimicrob. Agents Chemother.* 2016, 60, 532–536. [CrossRef] [PubMed]

87. Dietl, A.M.; Misslinger, M.; Aguiar, M.M.; Ivashov, V.; Teis, D.; Pfister, J.; Decristofoforo, C.; Hermann, M.; Sullivan, S.M.; Smith, L.R.; et al. The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397. *Antimicrob. Agents Chemother.* 2019, 63, e00807-19. [CrossRef]

88. Bowman, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. *Antimicrob. Agents Chemother.* 2002, 46, 3001–3012. [CrossRef]

89. Wiederhold, N.P. The antifungal arsenal: Alternative drugs and future targets. *Int. J. Antimicrob. Agents 2018, 51, 333–339. [CrossRef] [PubMed]

90. Arendrup, M.C.; Jensen, R.H.; Cuenca-Estrella, M. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms. *Antimicrob. Agents Chemother.* 2016, 60, 532–536. [CrossRef] [PubMed]

91. Rubino, C.M.; Smith, L.R.; Mannen, M.P.; Hopkins, A.M.; Lakota, E.A.; Sullivan, S.M. Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis. *Open Forum Infect. Dis.* 2017, 4, S473. [CrossRef]

92. Bogdan, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. *Antimicrob. Agents Chemother.* 2002, 46, 3001–3012. [CrossRef]
90. Berkow, E.L.; Angulo, D.; Lockhart, S.R. In Vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of *Candida auris*. *Antimicrob. Agents Chemother.* 2017, 61, e00435-17. [CrossRef] [PubMed]

91. Larkin, E.L.; Long, L.; Isham, N.; Borroto-Esoda, K.; Barat, S.; Angulo, D.; Wiring, S.; Ghannoum, M. A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. *Antimicrob. Agents Chemother.* 2019, 63, e02611-18. [CrossRef] [PubMed]

92. Danby, C.S.; Boikov, D.; Rautema-Richardson, R.; Sobel, J.D. Effect of pH on in vitro susceptibility of *Candida glabrata* and *Candida albicans* to 11 antifungal agents and implications for use. *Antimicrob. Agents Chemother.* 2012, 56, 1403–1406. [CrossRef] [PubMed]

93. Spitzer, M.; Wiederhold, N.P. Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications. *J. Low. Genit. Tract Dis.* 2018, 22, 152–158. [CrossRef] [PubMed]

94. Rivero-Mendez, O.; Soto-Debran, J.C.; Cuenca-Estrella, M.; Alastruey-Izquierdo, A. In Vitro Activity of Ibrexafungerp against Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies. *J. Fungi* 2021, 7, 232. [CrossRef]

95. Jiménez-Ortigosa, C.; Paderu, P.; Motyl, M.R.; Perlin, D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. *Antimicrob. Agents Chemother.* 2014, 58, 1248–1251. [CrossRef]

96. Lamoth, F.; Alexander, B.D. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. *Antimicrob. Agents Chemother.* 2015, 59, 4308–4311. [CrossRef]

97. Park, S.; Kelly, R.; Kahn, J.N.; Robles, J.; Hsu, M.J.; Register, E.; Li, W.; Vyas, V.; Fan, H.; Abruzzo, G.; et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical *Candida* sp. isolates. *Antimicrob. Agents Chemother.* 2005, 49, 3264–3273. [CrossRef] [PubMed]

98. Park, S.; Kelly, R.; Kahn, J.N.; Robles, J.; Hsu, M.J.; Register, E.; Li, W.; Vyas, V.; Fan, H.; Abruzzo, G.; et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical *Candida* sp. isolates. *Antimicrob. Agents Chemother.* 2005, 49, 3264–3273. [CrossRef] [PubMed]

99. Nunnally, N.S.; Etienne, K.A.; Angulo, D.; Lockhart, S.R.; Berkow, E.L. In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against *Candida glabrata* Isolates with FKS Mutations. *Antimicrob. Agents Chemother.* 2019, 63, e01692-19. [CrossRef] [PubMed]

100. Jallow, S.; Govender, N.P. Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. *J. Fungi* 2021, 7, 163. [CrossRef] [PubMed]

101. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Pizzini, J.; Catano, G.; Patterson, T.F. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant *Candida glabrata*. *J. Antimicrob. Chemother.* 2018, 73, 448–451. [CrossRef] [PubMed]

102. Zhu, Y.C.; Barat, S.A.; Borroto-Esoda, K.; Angulo, D.; Chaturvedi, S.; Chaturvedi, V. Pan-resistant *Candida auris* isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). *Int. J. Fungi* 2020, 55, 105922. [CrossRef] [PubMed]

103. Ghannoum, M.; Long, L.; Isham, N.; Hager, C.; Wilson, R.; Borroto-Esoda, K.; Barat, S.; Angulo, D. Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against *Candida glabrata*. *Antimicrob. Agents Chemother.* 2019, 63, e01510-19. [CrossRef] [PubMed]

104. Marcos-Zambrano, L.J.; Gomez-Perosanz, M.; Bouza, E.; Guinea, J. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic *Candida* spp. *J. Antimicrob. Chemother.* 2017, 72, 1969–1976. [CrossRef]

105. Pfaller, M.A.; Messer, S.A.; Romberg, P.R.; Borroto-Esoda, K.; Castanheira, M. Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of *Candida Species*. *Antimicrob. Agents Chemother.* 2017, 61, e00161-17. [CrossRef]

106. Mesquida, A.; Diaz-Garcia, J.; Sanchez-Carrillo, C.; Martin-Rabadan, P.; Alcala, L.; Munoz, P.; Escibarano, P.; Guinea, J. AF659 and F659R substitutions at the HS1 of FKS1 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against *Candida glabrata*. *Clin. Microbiol. Infect.* 2022, 28, 1154.e5–1154.e8. [CrossRef]

107. Lepak, A.J.; Marchillo, K.; Andes, D.R. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. *Antimicrob. Agents Chemother.* 2015, 59, 1265–1272. [CrossRef]

108. Wiederhold, N.P.; Najvar, L.K.; Olivo, M.; Morris, K.N.; Patterson, H.P.; Catano, G.; Patterson, T.F. Ibrexafungerp Demonstrates In Vitro Activity against Fluconazole-Resistant *Candida auris* and In Vivo Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis. *Antimicrob. Agents Chemother.* 2021, 65, e0294-20. [CrossRef] [PubMed]

109. Barat, S.A.; Borroto-Esoda, K.; Angulo, D.; Ashbaugh, A.; Cushion, M. Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Treatment Model of Pneumocystis Pneumonia. In Proceedings of the ASM Microbe, San Francisco, CA, USA, 20–24 June 2019.

110. Wring, S.A.; Randolph, R.; Park, S.; Abruzzo, G.; Chen, Q.; Flattery, A.; Garrett, G.; Peel, M.; Outcalt, R.; Powell, K.; et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthase Inhibitor, in Murine Models of Disseminated Candidiasis. *Antimicrob. Agents Chemother.* 2017, 61, e02068-16. [CrossRef] [PubMed]

111. Andes, D.; Diekema, D.J.; Pfaller, M.A.; Bohrmuller, J.; Marchillo, K.; Lepak, A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. *Antimicrob. Agents Chemother.* 2010, 54, 2497–2506. [CrossRef]
133. Hager, C.L.; Larkin, E.L.; Long, L.A.; Ghannoum, M.A. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J. Antimicrob. Chemother. 2018, 73, 2085–2088. [CrossRef]

134. Zhao, Y.; Prideaux, B.; Nagasaki, Y.; Lee, M.H.; Chen, P.Y.; Blanc, L.; Ho, H.; Clancy, C.J.; Nguyen, M.H.; Dartois, V.; et al. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrob. Agents Chemother. 2017, 61, e01099-17. [CrossRef] [PubMed]

135. Zhao, Y.; Perez, W.B.; Jimenez-Ortigosa, C.; Hough, G.; Locke, J.B.; Ong, V.; Bartizal, K.; Perlin, D.S. CD101: A novel long-acting echinocandin. Cell. Microbiol. 2016, 18, 1308–1316. [CrossRef]

136. Long, L.; Herrada, J.; Caley, D.; Munguba, G.; Sherif, R.; Bartizal, K.; Ghannoum, M.A. Evaluation of the efficacy of rezafungin in the treatment of Candida albicans endophthalmitis using a rabbit model. In Proceedings of the European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, 18–21 April 2020.

137. Miesel, L.; Lin, K.Y.; Ong, V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol. Res. Perspect. 2019, 7, e00546. [CrossRef]

138. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Wickes, B.L.; Catano, G.; Patterson, T.F. Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus. Antimicrob. Agents Chemother. 2019, 63, e01165-19. [CrossRef]

139. Cushion, M.T.; Ashbaugh, A. The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models. J. Fungi 2021, 7, 747. [CrossRef]

140. Lakota, E.A.; Bader, J.C.; Ong, V.; Bartizal, K.; Miesel, L.; Andes, D.R.; Bhavnani, S.M.; Rubino, C.M.; Ambrose, P.G.; Lepak, A.J. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrob. Agents Chemother. 2017, 61, e00758-17. [CrossRef]

141. Wiederhold, N.P.; Kontoyiannis, D.P.; Chi, J.; Prince, R.A.; Tam, V.H.; Lewis, M.L.; Fothergill, A.W.; Wiederhold, N.P.; Barker, B.M.; Lewis, E.R.; Doyle, A.L.; Kelly, S.L. The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51. Antimicrob. Agents Chemother. 2016, 60, 6872–6879. [CrossRef]

142. Flanagan, S.; Goodman, D.B.; Jandourek, A.; O’Reilly, T.; Sandison, T. Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Clinical Subjects. Antimicrob. Agents Chemother. 2020, 9, 456–465. [CrossRef] [PubMed]

143. Thompson, G.R.; Soriano, A.; Skoutelas, A.; Vazquez, J.A.; Honore, P.M.; Horcajada, J.P.; Sparen, H.; Bassetti, M.; Ostrosky-Zeichner, L.; Das, A.F.; et al. Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis-The STRIVE Trial. Clin. Infect. Dis. 2021, 73, 561–562. [CrossRef] [PubMed]

144. Ong, V.; Hough, G.; Schlosser, M.; Bartizal, K.; Balkovec, J.M.; James, K.D.; Krishnan, B.R. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. Antimicrob. Agents Chemother. 2016, 60, 6872–6879. [CrossRef] [PubMed]

145. Hoekstra, W.J.; Garvey, E.P.; Moore, W.R.; Rafferty, S.W.; Yates, C.M.; Schotzinger, R.J. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 3455–3458. [CrossRef]

146. Warrillow, A.G.; Hull, C.M.; Parker, J.E.; Garvey, E.P.; Hoekstra, W.J.; Moore, W.R.; Schotzinger, R.J.; Kelly, D.E.; Kelly, S.L. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob. Agents Chemother. 2014, 58, 7121–7127. [CrossRef] [PubMed]

147. Warrillow, A.G.; Parker, J.E.; Price, C.L.; Nes, W.D.; Garvey, E.P.; Hoekstra, W.J.; Schotzinger, R.J.; Kelly, D.E.; Kelly, S.L. The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme. Antimicrob. Agents Chemother. 2016, 60, 4530–4538. [CrossRef]

148. Warrillow, A.G.S.; Parker, J.E.; Price, C.L.; Garvey, E.P.; Hoekstra, W.J.; Schotzinger, R.J.; Wiederhold, N.P.; Nes, W.D.; Kelly, D.E.; Kelly, S.L. The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51. Antimicrob. Agents Chemother. 2017, 61, e00333-17. [CrossRef]

149. Shubitz, L.F.; Trinh, H.T.; Galgiani, J.N.; Lewis, M.L.; Fothergill, A.W.; Wiederhold, N.P.; Barker, B.M.; Lewis, E.R.; Doyle, A.L.; Hoekstra, W.J.; et al. Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. Antimicrob. Agents Chemother. 2015, 59, 7249–7254. [CrossRef]

150. Lockhart, S.R.; Fothergill, A.W.; Iqbal, N.; Bolden, C.B.; Grossman, N.T.; Garvey, E.P.; Brand, S.R.; Hoekstra, W.J.; Schotzinger, R.J.; Ottinger, E.; et al. The Investigational Fungal Cyp51 Inhibitor VT-1129 Proves Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob. Chemother. 2016, 60, 2528–2531. [CrossRef]

151. Nishimoto, A.T.; Whaley, S.G.; Wiederhold, N.P.; Zhang, Q.; Yates, C.M.; Hoekstra, W.J.; Schotzinger, R.J.; Garvey, E.P.; Rogers, P.D. Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161. Antimicrob. Agents Chemother. 2019, 63, e01304-19. [CrossRef]

152. Nishimoto, A.T.; Wiederhold, N.P.; Flowers, S.A.; Zhang, Q.; Kelly, S.L.; Morschhauser, J.; Yates, C.M.; Hoekstra, W.J.; Schotzinger, R.J.; Garvey, E.P.; et al. In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans. Antimicrob. Agents Chemother. 2019, 63, e00341-19. [CrossRef] [PubMed]

153. Schell, W.A.; Jones, A.M.; Garvey, E.P.; Hoekstra, W.J.; Schotzinger, R.J.; Alexander, B.D. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. Antimicrob. Agents Chemother. 2017, 61, e01817-16. [CrossRef] [PubMed]

154. Monk, B.C.; Keniya, M.V.; Sabherwal, M.; Wilson, R.K.; Graham, D.O.; Hassan, H.F.; Chen, D.; Tyndall, J.D.A. Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161. Antimicrob. Agents Chemother. 2019, 63, e02114-18. [CrossRef] [PubMed]
155. Garvey, E.P.; Hoekstra, W.J.; Schotzinger, R.J.; Sobel, J.D.; Lilly, E.A.; Fidel, P.L., Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. *Antimicrob. Agents Chemother.* 2015, 59, 5567–5573. [CrossRef]

156. Garvey, E.P.; Hoekstra, W.J.; Moore, W.R.; Schotzinger, R.J.; Long, L.; Ghannoum, M.A. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. *Antimicrob. Agents Chemother.* 2015, 59, 1992–1997. [CrossRef]

157. Break, T.J.; Desai, J.V.; Natarajan, M.; Ferre, E.M.N.; Henderson, C.; Zelazny, A.M.; Siebenlist, U.; Hoekstra, W.J.; Schotzinger, R.J.; Garvey, E.P., et al. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans. *J. Antimicrob. Chemother.* 2018, 73, 151–155. [CrossRef]

158. Wiederhold, N.P.; Shubitz, L.F.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Catano, G.; Trinh, H.T.; Yates, C.M.; Schotzinger, R.J.; Garvey, E.P., et al. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by *Coccidioides posadasii* and *Coccidioides immitis*. *Antimicrob. Agents Chemother.* 2018, 62, e02258-17. [CrossRef]

159. Gebremariam, T.; Wiederhold, N.P.; Fothergill, A.W.; Garvey, E.P.; Hoekstra, W.J.; Patterson, T.F.; Filler, S.G.; Ibrahim, A.S. VT-1161 Protects Immunosuppressed Mice from *Rhizopus arrhizus* var. *arrhizus* Infection. *Antimicrob. Agents Chemother.* 2015, 59, 7815–7817. [CrossRef]

160. Vivjoa. *Vivjoa (Oteseconazole) Package Insert*; Vivjoa: Durham, NC, USA, 2022.

161. Sobel, J.D.; Nyirjesy, P. Oteseconazole: An advance in treatment of recurrent vulvovaginal candidiasis. *Future Microbiol.* 2021, 16, 1453–1461. [CrossRef]

162. Brand, S.R.; Degenhardt, T.P.; Person, K.; Sobel, J.D.; Nyirjesy, P.; Schotzinger, R.J.; Tavakkol, A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. *Am. J. Obstet. Gynecol.* 2018, 218, e621.e1–e624.e9. [CrossRef] [PubMed]

163. Brand, S.R.; Sobel, J.D.; Nyirjesy, P.; Ghannoum, M.A.; Schotzinger, R.J.; Degenhardt, T.P. A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. *Clin. Infect. Dis.* 2021, 73, e1518–e1524. [CrossRef] [PubMed]

164. Elewski, B.; Brand, S.; Degenhardt, T.; Curelop, S.; Pollak, R.; Schotzinger, R.; Tavakkol, A. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. *Br. J. Dermatol.* 2021, 184, 270–280. [CrossRef] [PubMed]

165. Cass, L.; Murray, A.; Davis, A.; Woodward, K.; Albayaty, M.; Ito, K.; Strong, P.; Ayrton, J.; Brindley, C.; Prosser, J.; et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. *Pharmacol. Res. Perspect.* 2021, 9, e00690. [CrossRef]

166. Colley, T.; Alanio, A.; Kelly, S.L.; Sehra, G.; Kizawa, Y.; Warrillow, A.G.S.; Parker, J.E.; Kelly, D.E.; Kimura, G.; Anderson-Dring, L.; et al. In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on *Aspergillus fumigatus* Infection. *Antimicrob. Agents Chemother.* 2017, 61, e02280-16. [CrossRef]

167. Santangelo, R.; Paderu, P.; Delmas, G.; Chen, Z.W.; Mannino, R.; Zari, L.; Perlin, D.S. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. *Antimicrob. Agents Chemother.* 2000, 44, 2356–2360. [CrossRef]

168. Kibathi, L.; Kumar, P.; Lionakis, M.; Urban, A.; Ferre, E.; McManus, M.; Colton, B.; Lambros, C.; Lu, R.; Mannino, R.; et al. A phase lla efficacy safety, tolerability and pharmacokinetic study of encocchleated amphotericin B in patients with mucocutaneous (esophageal, oropharyngeal, vulvovaginal) Candidiasis who are refractory or intolerant to standard non-intravenous therapies. *Open Forum Infect. Dis.* 2018, 5, S435. [CrossRef]